A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis

Inclusion Criteria

• •1. Histologically-confirmed, ER negative, PR negative and Her2 negative adenocarcinoma of the breast with brain lesion on radiographic imaging.
• •2. ECOG Performance Status of 0-2.
• •3. Life expectancy of \>12 weeks.
• •4. No limit to prior therapies with last anti-cancer treatment ≥ 2 weeks from initiation of protocol-based therapy provided all toxicities (other than alopecia) have resolved to ≤Grade 1 or baseline.
• •5. No active serious infection or other comorbid illness which would impair ability to participate in the trial.
• •6. Stable or decreasing dose of steroids for ≥ 7 days.
• •7. Interval ≥ 4 weeks between open brain biopsy and initiation of protocol-based therapy.
• •8. Patients must have adequate organ function.